The Bill and Melinda Gates Foundation is a charitable organization that has spent tens of billions of dollars fighting global ...

As weight-loss drugs have exploded in popularity this past year, part of the craze has been members of the public wondering which celebrities are on Ozempic.

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

Skuffende data for vægttabsmidlet Cagrisema sendte Novo Nordisk-aktien ned med 20,7 procent fredag Novo Nordisk-aktien styrdykkede med over 20 procent fredag efter offentliggørelsen af ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

Novo Nordisk (NVO) is down -20.0%, or -$20.66 to $82.78. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug ...

Inside the Beltway, the move is often portrayed as a demotion, but some of these former members find themselves representing more people in their new roles, along with having more influence and a ...

Former President Obama aides argued it’s becoming "easier and easier to forget" that President-elect Trump isn’t in the White House yet, with President Biden almost absent from the public eye ...

This story was updated to add new information. The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations ...

Novo Nordisk, for its part, has been working hard to enrich its cardiometabolic pipeline in areas beyond diabetes and obesity, where the company currently dominates the commercial market with its ...